Patent office india published patent information - august 12th, 2011

6,090 views

Published on

Published in: Business
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
6,090
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
18
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Patent office india published patent information - august 12th, 2011

  1. 1. ¯Öê™ëü™ü úÖµÖÖÔ»ÖµÖ úÖ ¿ÖÖÃ֍úßµÖ •Ö−ÖÔ»Ö OFFICIAL JOURNAL OF THE PATENT OFFICE×−֐ÖÔ´Ö−Ö ÃÖÓ. 32/2011 ¿ÖãÎú¾ÖÖ¸ü פü−ÖÖӍú: 12/08/2011ISSUE NO. 32/2011 FRIDAY DATE: 12/08/2011 ¯Öê™ëü™ü úÖµÖÖÔ»ÖµÖ úÖ ‹ú ¯ÖύúÖ¿Ö−Ö PUBLICATION OF THE PATENT OFFICE The Patent Office Journal 12/08/2011 13337
  2. 2. INTRODUCTIONIn view of the recent amendment made in the Patents Act, 1970 by the Patents (Amendment) Act, 2005effective from 01st January 2005, the Official Journal of The Patent Office is required to be publishedunder the Statute. This Journal is being published on weekly basis on every Friday covering the variousproceedings on Patents as required according to the provision of Section 145 of the Patents Act 1970. All theenquiries on this Official Journal and other information as required by the public should be addressed to theController General of Patents, Designs & Trade Marks. Suggestions and comments are requested from allquarters so that the content can be enriched. (P H Kurian) CONTROLLER GENERAL OF PATENTS, DESIGNS & TRADE MARKS12 TH AUGST, 2011 The Patent Office Journal 12/08/2011 13338
  3. 3. CONTENTS SUBJECT PAGE NUMBERJURISDICTION : 13340 – 13341SPECIAL NOTICE : 13342 – 13343PUBLICATION U/S. 87(1) : 13344 – 13363EARLY PUBLICATION (DELHI) : 13364 – 13365EARLY PUBLICATION (MUMBAI) : 13366 – 13369EARLY PUBLICATION (CHENNAI) : 13370 – 13377EARLY PUBLICATION (KOLKATA) 13378 – 13379PUBLICATION AFTER 18 MONTHS (DELHI) : 13380 – 13392PUBLICATION AFTER 18 MONTHS (MUMBAI) : 13393 – 13407PUBLICATION AFTER 18 MONTHS (CHENNAI) : 13408 – 13686PUBLICATION AFTER 18 MONTHS ( KOLKATA ) : 13687 – 13728AMENDMENT UNDER SEC.57. (KOLKATA) : 13729PUBLICATION UNDER SECTION 43(2) INRESPECT OF THE GRANT (DELHI) : 13730PUBLICATION UNDER SECTION 43(2) INRESPECT OF THE GRANT (MUMBAI) : 13731 – 13732PUBLICATION UNDER SECTION 43(2) INRESPECT OF THE GRANT (CHENNAI) : 13733PUBLICATION UNDER SECTION 43(2) INRESPECT OF THE GRANT (KOLKATA) : 13734INTRODUCTION TO DESIGN PUBLICATION : 13735COPYRIGHT PUBLICATION : 13736REGISTRATION OF DESIGNS : 13737 - 13786 The Patent Office Journal 12/08/2011 13339
  4. 4. THE PATENT OFFICE KOLKATA, 12/08/2011 Address of the Patent Offices/Jurisdictions The following are addresses of all the Patent Offices located at different places having their Territorial Jurisdiction on a Zonal basis as shown below:-1 Office of the Controller General of Patents, 4 The Patent Office, Designs & Trade Marks, Government of India, Boudhik Sampada Bhavan, Intellectual Property Rights Building, Near Antop Hill Post Office,S.M.Road,Antop Hill, G.S.T. Road, Guindy, Mumbai – 400 037 Chennai – 600 032. Phone: (91)(22) 24123311, Phone: (91)(44) 2250 2081-84 Fax : (91)(22) 24123322 Fax : (91)(44) 2250 2066 E-mail: cgpdtm@nic.in E-mail: chennai-patent@nic.in The States of Andhra Pradesh, Karnataka, Kerala, Tamil Nadu and the Union Territories of Puducherry and Lakshadweep.2 The Patent Office, Government of India, 5 The Patent Office (Head Office), Boudhik Sampada Bhavan, Government of India, Near Antop Hill Post Office,S.M.Road,Antop Hill, Boudhik Sampada Bhavan, Mumbai – 400 037 CP-2, Sector –V, Salt Lake City, Phone: (91)(22) 24137701 Kolkata- 700 091 Fax: (91)(22) 24130387 E-mail: mumbai-patent@nic.in Phone: (91)(33) 2367 1943/44/45/46/87 The States of Gujarat, Maharashtra, Madhya Fax: (91)(33) 2367 1988 Pradesh, Goa and Chhattisgarh and the Union E-Mail: kolkata-patent@nic.in Territories of Daman and Diu & Dadra and Nagar Haveli Rest of India3 The Patent Office, Government of India, Boudhik Sampada Bhavan, Plot No. 32., Sector-14, Dwarka, New Delhi – 110075 Phone: (91)(11) 2808 1921 – 25 Fax: (91)(11) 2808 1920 & 2808 1940 E.mail: delhi-patent@nic.in The States of Haryana, Himachal Pradesh, Jammu and Kashmir, Punjab, Rajasthan, Uttar Pradesh, Uttaranchal, Delhi and the Union Territory of Chandigarh. Website: www.ipindia.nic.in www.patentoffice.nic.in All applications, notices, statements or other documents or any fees required by the Patents Act, 1970 and The Patents (Amendment) Act, 2005 or by the Patents (Amendment) Rules, 2006 will be received only at the appropriate offices of the Patent Office. Fees: The Fees may either be paid in cash or may be sent by Bank Draft or Cheques payable to the Controller of Patents drawn on a scheduled Bank at the place where the appropriate office is situated. The Patent Office Journal 12/08/2011 13340
  5. 5. ¯Öê™ëü™ü úÖµÖÖÔ»ÖµÖ úÖê»ÖúÖŸÖÖ, פü−ÖÖӍ 12/08/2011 úÖµÖÖÔ»ÖµÖÖë êú Öê¡ÖÖ׬֍úÖ¸ü êú ¯ÖŸÖê ×¾Ö×³Ö®Ö •ÖÖÆüÖë ¯Ö¸ü ÛÃ£ÖŸÖ ¯Öê™êü−™ü úÖµÖÖÔ»ÖµÖ êú ¯ÖŸÖê †ÖÓ“Ö׻֍ú †Ö¬ÖÖ¸ü ¯Ö¸ü ¤üÙ¿ÖŸÖ ˆ−֍úê ¯ÖÏÖ¤êü׿֍ú †×¬ÖúÖ¸ü Öê¡Ö êú ÃÖÖ£Ö −Öß“Öê פü‹ Ö‹ Æïü :-1 úÖµÖÖÔ»ÖµÖ: ´ÖÆüÖ×−ÖµÖӡ֍ú, ‹úþÖ, †×³Öú»¯Ö 4 ¯Öê™ëü™ü úÖµÖÖÔ»ÖµÖ “Öê®Ö‡Ô, ŸÖ£ÖÖ ¾µÖÖ¯ÖÖ¸ü דÖÅ−Ö, ‡Ó™êü»ÖꌓÖã†»Ö ¯ÖÏÖê¯Ö™üá ¸üÖ‡™ËüÃÖ ×²ÖÜ»›üÖ ‹−Ö™üÖò¯Ö ×Æü»Ö ›üü֍ú‘Ö¸ êú ÃÖ´Ö߯Öü, ‡Ó›üÛÙÒüµÖ»Ö ‡Ã™êü™ü ‹ÃÖ. ‹´Ö. ¸üÖê›ü, ‹ÃÖ†Ö‡Ô›üßÃÖ߆Öê †Ö¸ü‹´Ö›üß ÖÖê›üÖˆ−Ö ‹×¸üµÖÖ ‹−Ö™üÖò¯Ö ×Æü»Ö, ´Öã´²Ö‡Ô -400 037, ³ÖÖ¸üŸÖ. ‹›ü•ÖÃÖê−™ü ™ãü ‡ÔÖ»Ö °»ÖÖÍú ±úÖê−Ö: (91)(22) 24123311 •Öß.‹ÃÖ.™üß. ¸üÖê›ü, ÖÖµÖ−›üß, ±îúŒÃÖ: (91)(22) 24123322 “Öê®Ö‡Ô - 600 032. ‡Ô.´Öê»Ö: cgpdtm@nic.in ±úÖê−Ö: (91)(44) 2250 2081-84 ±îúŒÃÖ: (91)(44) 2250-2066 ‡Ô.´Öê»Ö: chennai-patent@nic.in †Ö−¬ÖÐ ¯ÖϤêü¿Ö, ú−ÖÖÔ™üú, êú¸ü»Ö, ŸÖ×´Ö»Ö−ÖÖ›ãü ŸÖ£ÖÖ ¯Öã›ãü“Öê¸üß ¸üÖ•µÖ Öê¡Ö ‹¾ÖÓ ÃÖÓ‘Ö ¿ÖÖ×ÃÖŸÖ Öê¡Ö, »ÖÖ«ü߯Ö2 ¯Öê™ëü™ü úÖµÖÖÔ»ÖµÖ, ³ÖÖ¸üŸÖ ÃÖ¸üúÖ¸ ²ÖÖîרüú ÃÖÓ¯Ö¤üÖ ³Ö¾Ö−Ö, 5 ¯Öê™ëü™ü úÖµÖÖÔ»ÖµÖ úÖê»ÖúÖŸÖÖ (¯ÖϬÖÖ−Ö úÖµÖÖÔ»ÖµÖ), ‹−Ö™üÖò¯Ö ×Æü»Ö ›üü֍ú‘Ö¸ êú ÃÖ´Ö߯Öü, ²ÖÖîרüú ÃÖÓ¯Ö¤üÖ ³Ö¾Ö−Ö, ‹ÃÖ. ‹´Ö. ¸üÖê›ü, ÃÖ߯Öß-2, ÃÖꌙü¸ü-V, ÃÖÖ»™ü »Öêú ×ÃÖ™üß, ‹−Ö™üÖò¯Ö ×Æü»Ö, ´Öã´²Ö‡Ô - 400 037, úÖê»ÖúÖŸÖÖ- 700 091, ³ÖÖ¸üŸÖ. ±úÖê−Ö: (91)(22) 2413 7701, ±úÖê−Ö: (91)(33) 2367 1943/44/45/46/87 ±îúŒÃÖ: (91)(22) 2413 0387 ±îúŒÃÖ/Fax: (91)(33) 2367 1988 ‡Ô.´Öê»Ö: mumbai-patent@nic.in ‡Ô.´Öê»Ö: kolkata-patent@nic.in Öã•Ö¸üÖŸÖ, ´ÖÆüÖ¸üÖ™Òü, ´Ö¬µÖ ¯ÖϤêü¿Ö, ÖÖê†Ö ŸÖ£ÖÖ ”û¢ÖßÃ֐֜Íü ¸üÖ•µÖ Öê¡Ö ‹¾ÖÓ ÃÖÓ‘Ö ¿ÖÖ×ÃÖŸÖ Öê¡Ö, ¤ü´Ö−Ö ŸÖ£ÖÖ ¤üß¾Ö, ¤üÖ¤ü¸ü ³ÖÖ¸üŸÖ úÖ †¾Ö¿ÖêÂÖ Öê¡Ö †Öî¸ü −֐ָü Æü¾Öê»Öß.3 ¯Öê™ëü™ü úÖµÖÖÔ»ÖµÖ ×¤ü»»Öß, ²ÖÖîרüú ÃÖÓ¯Ö¤üÖ ³Ö¾Ö−Ö, ¯»ÖÖò™ü ÃÖÓ. 32, ÃÖꌙü¸ü - 14, «üÖ¸üúÖ, −Ö‡Ô ×¤ü»»Öß - 110 075. ±úÖê−Ö: (91)(11) 2808 1921-25 ±îúŒÃÖ: (91)(11) 2808 1920, 2808 1940 ‡Ô.´Öê»Ö: delhi-patent@nic.in Æü׸üµÖ֝ÖÖ, ×Æü´ÖÖ“Ö»Ö ¯ÖϤêü¿Ö, •Ö´´Öæ ŸÖ£ÖÖ ú¿´Ö߸ü, ¯ÖÓ•ÖÖ²Ö, ¸üÖ•ÖãÖÖ−Ö, ˆ¢Ö¸ü ¯ÖϤêü¿Ö, פü»»Öß ŸÖ£ÖÖ ˆ¢Ö¸üÖÓ“Ö»Ö ¸üÖ•µÖ Öê¡ÖÖë, ‹¾ÖÓ ÃÖÓ‘Ö ¿ÖÖ×ÃÖŸÖ Öê¡Ö “ÖÓ›üߐ֜Íü ¾Öê²ÖÃÖÖ‡™ü: http://www.ipindia.nic.in www.patentoffice.nic.in¯Öê™ëü™ü †×¬Ö×−ÖµÖ´Ö, 1970 ŸÖ£ÖÖ ¯Öê™ëü™ü (ÃÖÓ¿ÖÖê¬Ö−Ö) †×¬Ö×−ÖµÖ´Ö, 2005 †£Ö¾ÖÖ ¯Öê™ëü™ü (ÃÖÓ¿ÖÖê¬Ö−Ö) ×−ÖµÖ´Ö, 2006 «üÖ¸üÖ ¾ÖÖÓ×”ûŸÖ ÃÖ³Öß †Ö¾Öê¤ü−Ö,ÃÖæ“Ö−ÖÖ‹Ñ, ×¾Ö¾Ö¸üÖ µÖÖ †−µÖ ¤üßÖÖ¾Öê•Ö µÖÖ úÖê‡Ô ¿Ö㻍ú ¯Öê™ëü™ü úÖµÖÖÔ»ÖµÖ êú êú¾Ö»Ö ˆ¯ÖµÖãŒŸÖ úÖµÖÖÔ»ÖµÖ ´Öë þÖߍéúŸÖ ÆüÖëÖê …¿Ö㻍ú: ¿Ö㻍ú µÖÖ ŸÖÖê −֍ú¤ü ºþ¯Ö ´Öë µÖÖ "Controller of Patents" êú −ÖÖ´Ö ´Öë ¤êüµÖ ²Öïú ›ÒüÖ°™ü µÖÖ “Öêú êú «üÖ¸üÖ ³Öê•Öß •ÖÖ Ã֍úŸÖß Æîü •ÖÖê ˆÃÖß Ã£ÖÖ−Ö êú ׍úÃÖ߆−ÖãÃÖæ×“ÖŸÖ ²Öïú ´Öë ¯ÖϤü¢Ö ÆüÖê •ÖÆüÖÑ ˆ¯ÖµÖãŒŸÖ úÖµÖÖÔ»ÖµÖ ÛÃ£ÖŸÖ Æïü… The Patent Office Journal 12/08/2011 13341
  6. 6. SPECIAL NOTICE 18 Months publication as required under Section 11A of the Patents Act, 1970 as amended by the Patents (Amendment) Act, 2005.Notice is hereby given that any person at any time before the grant of Patent may give representation by wayof opposition to the Controller of Patents at appropriate office on the ground and in a manner specified undersection 25(1) of the Patents (Amendment) Act, 2005 read with Rule 55 of the Patents (Amendment) Rules,2006.Notice is also given that if any interested person requests for copies of the complete specification, drawingand abstract of any application already published, the photocopy of the same can be supplied by the PatentOffice as per the jurisdiction on payment of prescribed fees of Rs.4/- per page. If any further details arerequired to be obtained, the same can be provided by the respective Patent Offices on request. (P H Kurian) CONTROLLER GENERAL OF PATENTS, DESIGNS & TRADE MARKS The Patent Office Journal 12/08/2011 13342
  7. 7. SPECIAL NOTICE Under the new provision of the Patents Act, 1970 as amended by the Patents (Amendment) Act,2005 and Rules there under, Publication of the matter relating to Patents in the Official Gazette of India PartIII, Section 2 has been discontinued and instead “The Official Journal of the Patent Office” is beingpublished containing all the activities of The Patent Office such as publication of all the patent applicationsafter 18th months , grant of patents & all other information in respect of the proceedings as required underthe provisions of the Patents (Amendment) Act, 2005 and Rules thereunder on weekly basis on everyFriday.The Journal is uploaded in the website every Friday. So Paper form and CD-ROM form of the Journal arediscontinued from 01/01/2009. SPECIAL NOTICEEvery effort is being taken to publish all the patent applications under section 11(A) of the Patents Act.However, if duplication of publication of any application is found, then earlier date of publication will betaken for the purpose of provisional protection for applicant and Patent Office will grant Patent not beforesix months from the date of second publication, provided that there is there is no third party representation. The Patent Office Journal 12/08/2011 13343
  8. 8. PUBLICATION U/S. 87(1) The Compulsory licence Application No. C.L.A. No. 1 of 2011 from M/S. Natco Pharma Ltd. In Patent No. 215758 is hereby published (P H Kurian) CONTROLLER GENERAL OF PATENTS, DESIGNS & TRADE MARKS FORM 17 THE PATENTS ACT, 1970 (39 of 1970) & THE PATENT RULES, 2003 APPLICATIONFORCOMPULSORYLICENCE [See sections 84(1), 91, 92(1) or 92A; rule 96] We, NATCO PHARMA LIMITED, of NATCO House, Road No 2, Banjara Hills, Hyderabad 500 033, Andra Pradesh, India; hereby apply for the grant of a compulsory licence under Patent No. IN 215758, (formerlyIN/PCT/2001/00799/MUM), dated 28.03.2008, granted to BAYER CORPORATION of 100 Bayer Road, Pittsburgh, PA-15205-9741, USA on the following grounds namely:- As enclosed herewith We declare that the facts and matters stated herein are true to the best of my knowledge, information and belief. The details of the documentary evidence in support of my/our interest and the grounds stated above are given below: As enclosed herewith Our Address for service in India is, Rajeshwari and Associates, 1039, First Floor, C- Block, Sushant Lok-I, Gurgaon -122002, Haryana, India The Patent Office Journal 12/08/2011 13344
  9. 9. BEFORE THE CONTROLLER OF PATENTS, MUMBAII N THE MATTER OF:Natco Phartna Limited ... APPUCANT/PETITIONER VERSUS Bayer Corporation ... RESPONDENTIPATENTEEAPPLICATION UNDER SECTION 84(1) OF THE PATENTS ACT, 1970(AS AMENDED) FOR GRANT OF COMPULSORY LICENCE The Applicant abovenamed humbly submits as under : 1. About the Applicant: The Applicant herein is a company incorporated under the Companies Act 1956 and having its registered office at Natco House, Banjara Hills, Hyderabad. The Applicant was incorporated in the year 1981 and since then it has been in the business of research, development, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and Internationa! markets. From a humble beginning with 20 employees, the company has grown over the years into one with more than 2000 employees, including well trained scientists and researchers. The Applicant Companys core area of expertise lies in manufacture and development of anti-cancer drugs. The Patent Office Journal 12/08/2011 13345
  10. 10. Further details about the Applicant are set out and explained later in the present application.2. Subject matter of the present application: The present application for compulsory licence is being preferred in respect of a product called Sorafenib which is a compound said to be covered by Indian patent no. 215758 granted on 03.03.2008 to the Patentee. It is belived that the active pharmaceutical ingredient sorafenib is covered by this Patent. A copy of the Indian patent no.215758 granted on 03.03.2008 is annexed herewith at Annexure- A. The Applicant prays for leave to file certified copy of the Patent in due course. The said product being an inhibitor of several Tyrosine protein kinases (VEGFR and PDGFR) and RAf kinase is used for the treatment of primary kidney and advanced primary liver cancer. The said product is marketed under the brand name NEXAVAR by the Patentee. The Nexavar cost of therapy per month is Rs.2,80,428/-. A copy of the product label of Nexaver is annexed herewith as Annexure-B. 3. Hepatocellular Carcinoma Fact Sheet A. The Disease Hepatocellular carcinoma (HCC), also known as primary liver cancer, js the most common form of liver cancer and is responsible for 80 percent of the primary malignant liver tumors observed in adults (source: World Cancer Report, 2008 IARC Press 2008, page 180 to 185 is annexed herewith as Annexure-C). For patients diagnosed with HCC the prognosis is poor because symptoms usually do not appear until a late stage in the disease (A print out of the hyperlink Mayo Clinic, The Patent Office Journal 12/08/2011 13346
  11. 11. http://www.mayoclinic,com/heath/liver-cancer/DS00399/DSECTION= treatments-and-drugs is annexed herewith as Annexure-D) In other words, most cases of HCC are detected only at a very (late stage. B. Key Statistics • HCC is the fifth most common cancer worldwide (source: page 180) with a five-year relative survival rate of about seven percent. • HCC disproportionately affects men, with four times as many men developing HCC as women. • HCC causes more than 700,000 deaths annually worldwide. • In 2008 approximately 20,144 cases of HCC were reported in India, and more than 18,043 Indians died of HCC; The above information has been obtained from the following sources, copies of which are annexed hereto as Annexure-D. E. F, respectively: 1) Mayo Clinic Report. 2) World Cancer Report 2008 IARC Press, 2008 (page 224 to 229). 3) GLOBOCAN 2008: Cancer Incidence, Mortality and Prevalence India, IARC Press, 2008.4. Renal Cell Carcinoma Fact Sheet A. The Disease . Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, causing 85 percent of all kidney cancers, (source: American Foundation for Urologic Disease is annexed hereto as Annexure-G) The Patent Office Journal 12/08/2011 13347
  12. 12. • Despite advances in understanding the growth mechanisms of many different tumor types, kidney cancer is still not fully understood. It is believed that both the Ras signaling pathway and angiogenesis may play a role in kidney cancer,B. Key Statistics• Kidney cancer disproportionately affects men, with roughly twice as many men as women developing the disease annually.• The risk of kidney cancer increases with age. Over 90 percent of cases are diagnosed after age 45. The average age among newiy- diagnosed kidney cancer patients is 66, (source; Harvard Center for Cancer Prevention. Your Disease Risk: Kidney Cancer. Available at: http://www,diseaseriskindex.harvard.edu/update/hccpquiz.pl?lang = english&func=show&quiz=kidney&page=fact sheet)• At the time of diagnosis, normally the cancer has already metastasized (spread to distant body locations) in about one-third of people with kidney cancer, (source: American Foundation for Urologic Diseases)• For patients with early-stage kidney cancer, the five-year survival rate is between 70 and 98 percent (source: Globocon 2008). In later-stage disease, when the cancer has metastasized, the five- year survival rate is between 15 and 18 percent, (source: American Foundation for Uroiogical Diseases)• In 2008, about 8,900 Indians were diagnosed with kidney cancer, and about 5,733 died from the disease, (source: Harvard Center for Cancer Prevention. Your Disease Risk: Kidney Cancer, Available at: http://www.diseaseriskindex.harvard.edu/update/hccpquiz.pl?lanq= engiish&func=show&quiz = kidney&paqe=fact sheet) (source: The Patent Office Journal 12/08/2011 13348
  13. 13. GLOBOCAN 2008: Cancer Incidence, Mortality and Prevalence in India IARC Cancer IARC Press, 2008) The above information has been collected from the following sources, copy of which are annexed hereto as Annexure-G and Annexure-H respectively: i) American Foundation for Urologic Diseases. ii) Harvard Center for Cancer Prevention. Your Disease Risk: Kidney Cancer. Available at: http://www,diseaseriskindex.harvard.edu/update/hccpquiz.pl?la ng-enqlish&func=show&quiz-kidney&page=fact sheet.5. Position in India: It is submitted that at this point to the knowledge of the Petitioner, who has been in this field of treating cancer patients for over 20 years, there are at least 1,00,000 patients in India suffering from different forms and types of renal cell carcinoma and hepatic cell carcinoma, On an average, about 30,000 patients are diagnosed every year and added to the patient pool. Over 24000 patients die in India every year on account of these diseases.6. Treatment. Treatment-Liver Cancer•• Treatment options for HCC depend on the stage of the malignant disease, underlying liver function, which is a determinant of the usually co-existing cirrhosis, as well as the patients overall condition.•• The three main types of treatment for liver cancer are surgery (including liver transplantation), locoregional treatment modalities and The Patent Office Journal 12/08/2011 13349
  14. 14. chemotherapy. Sometimes two or more of these methods arecombined.Surgery offers the only chance to treat liver cancer. If the cancer isfound at an early stage and the rest of the liver is healthy, surgerywith or without liver transplantation may be curative, However, onlyabout 15% of patients have resectable disease (source: CancerResearch UK, http://www.cancerhelp.org.uk/help/defauit.asp?page=4917#chemo which is annexed hereto as Annexure-I) Evenafter surgery the five-year survival rate is only about 30 to 40 percent. Treatment - Kideny Cancer •• The treatment of RCC depends on the severity of the cancer and the patients overall health. The primary therapy for kidney cancer is surgery, which is effective only when all of the cancer is removed. Radiation treatment is also used when the cancer has spread beyond the kidney, (source: American Foundation for Urologic Disease) Immune modulators, such as interferon-alpha and interleukin-2 (IL- 2), are sometimes used, but response rates remain relatively low with these treatments (source: American Cancer Society. Detailed Guide: Kidney Cancer. Available at: http://www.cancer.org/Cancer/KidneyCancer/DetailedGuide/index printout is annexed hereto as Annexure-J) •• Chemotherapy - in some cases, since kidney cancer is resistant to chemotherapy. • Several newer forms of therapy that target specific parts of cancer cells have been used to treat people with advanced kidney cancer. These include drugs that stop angiogenesis (new blood vessel The Patent Office Journal 12/08/2011 13350
  15. 15. growth) and drugs that target other important cellular growth factors. One of such drugs is Sorafenib tosylate.Sorafenib:Sorafenib is prescribed by the physician, it is administered as 200mgtablet and the dosage per day is 800mg. which translates to two tabletsin the morning and two tablets in the night. The tablets must beconsumed till the tumor progression/ intolerable toxicity. Normally,patients with renal carcinoma may be covered and may receiveinsurance cover for nephrectomy; however patients do not receive anycover/assistance from Insurance companies for the use of the drugSorafenib. The drug Sorafenib has to be taken by the patientthroughout his lifetime,Treatment of diseases - Renal cell carcinoma and hepatic cell carcinoma.Drug - Sorafenib Tosylate.Dosage - 400 mg, twice a day (4 tablets a day).Duration of treatment - Lifetime.Price - Rs,2,80,428 per month per patient.Insurance - Nil.Survival rate:The survival rate in case of renal and hepatic carcinoma dependsentirely on the stage of the disease. In advanced metastatic renalcarcinoma, the survival rate is extremely poor and patients may live forfew months to 3-5 years. Hepatic cell carcinoma is even worst with asurvival rate of less than 10% and life span of not more than 12months. The Patent Office Journal 12/08/2011 13351
  16. 16. From the above it is clear that the product Sorafenib which is the subject of the present application is drawn to treat a gruesome disease that hardly has a cure and patients afflicted by this deadly disease if put on Sorafenib, must be given this treatment for their entire lifetime and should be able to access this drug irrespective of their caste, creed, affordability etc.7. The Patentee and Sorafenib: Sorafenib- limited availability: It is submitted that the product Sorafenib is exhorbitantly priced and limited in availability in India as explained below: a) Product imported: It is learnt that the Patentee Bayer Corporation imports and sells the drug sorafenib in India. To the knowledge of the Applicant, this product is not manufactured in India by the Respondent, The price of each tablet is Rs2337, As stated earlier, the average requirement per patient per month is about 120 tablets which works out to about Rs 2,80,428/- month and about Rs 33,65,136/- per year. Thus the product is exhorbitantly priced and almost out of reach of most of the people in India. b) Limited availability: The said product is available in pharmacies attached to certain hospitals and that too only in metro cities such as Mumbai, Chennai, Kolkata and Delhi. The product is often out of stock or not available in common pharmacies even in metro cities and in second tier or other smaller cities in India. Hence the product sold by the Patentee is extremely highly priced and is limited in availability. Currently, to the Bayer is operating with 12 distributors in India. To the knowledge of the Applicant, the Distributors are in Delhi, U.P., Punjab, Gujarat, West Bengal, Bihar, Vardman, Kerala and Tamil Nadu. There are no distributors atleast The Patent Office Journal 12/08/2011 13352
  17. 17. in the states of Madhya Pradesh, Jammu and Kashmir, Orissa, Rajasthan, Haryana, Chhattisgarh, Uttarakhand, Jharkhand, Himachal Pradesh, Assam, Arunachal Pradesh, Manipur, Meghalaya, Mizoram, Nagaland, Sikkim, Tripura, Rest of Maharastra, Goa, Pondicherry.c) It is estimated that though the Patentee sells the product, it reaches less than 1% of patients and almost 99 % of patients who are unable to afford the drug are left to die every year. According to GLOBOCAN data at least 30,000 patients are diagnosed every year who suffer from Liver and Kidney cancer. It is estimated that nearly 1,00,000 patients are currently suffering in India on these diseases. Of these, less than 1% of patients are catered to by the Rspondent Bayer. The remaining 99% of the patients do not receive any medication and thereby fall victim and die on account of this dreaded diseases.d) Requirement Vs. Availability As stated earlier, the approx member of patients in India suffering from RCC &. HLC is about 1,00,000. Since the prescribed regimen is 2 tablets a day, the total requirement per month = 120 tablets. Bayer does not manufacture the product Sorafenib in India. The number of Sorafenib tablet in the market is far less than the requirement under demand for the patients.e) Product Sorafenib found to be expensive in UK and US: It is important to note that in the UK, the National Health Service often subsidizes the price of important pharmaceuticals products such as The Patent Office Journal 12/08/2011 13353
  18. 18. those used for treatment of cancer. The NHS, after going through the price of Nexavar [which in UK works out to about £2504,60] and the schemes offered by the Patentee [buy 3 and get one free] found that the price of Nexavar is too expensive and NHS decided not to sponsor or subsidize the said drug under its schemes. The relevant information is available at the url: (source: http://www.advfn.com/nasdaq/StockNews.asps?stocknews =ONXX&article=40430330&headline=uk-watchdog-says- bayer-liver -drug-nexavar-too-expensive, a printout of which is annexed hereto as Annexure-K) Similarly, in US, the product Nexavar is not subsidized by any authority and the price is about USD 4300per month.S. Conclusion: In view of the above analysis, the Applicant submits that : a) more than three years from the date of grant of the patent no 215758 have elapsed [the patent was granted on 03-03-2008] and yet, the patentee Bayer has not taken adequate steps to manufacture in India and make full use of the invention; b) a prima facie case of reasonable requirements of the public not being satisfied is deemed to be made out because : i) the number of people who need access to the product Sorafenib to prolong their life or improve their health significantly exceeds those with actual access to the drug (60 -Vs- 3000)[1-% vs. 99%], and it) a substantial barrier to access the product is price; (Rs.2,80,482 per month) The Patent Office Journal 12/08/2011 13354
  19. 19. It is in these circumstances that the present application for compulsory licence is being preferred.9. Applicants interest: a) As stated in the foregoing paragraphs, the Applicant herein is a pharmaceutical company engaged in the manufacture of several anti-cancer products for last 20 years. Some of the products manufactured by the Applicant include Imatinib, Geftinib, Lenalidomide, etc, b) Why the Applicant prays for grant of compulsory licence: The Applicant herein submits that they have been performing research and development of various anti-cancer drugs. The applicant having known the plight of the cancer patients and the difficulties facilities faced by them, has decided to develop, manufacture and sell the said product Sorafenib to such needy patients irrespective of their location in India, at the lowest possible price so that access and availability of the drug is improved,The Applicant submits that this project is being undertaken is absolute bonafides, without any oblique commercial motives whatsoever. 10. Capability of the Applicant: The Applicant submits that as stated earlier, the Applicant is one of the foremost and leading pharmaceutical companies in India. The Applicant has its own manufacturing and marketing strengths as detailed below: a. Recognition of the R&D facilities: The Patent Office Journal 12/08/2011 13355
  20. 20. The Applicant submits that its R&D facilities conform to thestrictest standards adopted anywhere in the world. All thefacilities are GMP certified, and the Applicant follows GMPpractices as prescribed by the US FDA for both API andFormulation. (Copies of Awards and Certificates are producedherewith as Annexure-L)b. Facilities to manufacture sorafenib:In so far as the product Sorafenib is concerned, the Applicantherein does have the requisite technical know-how to developand manufacture the product Sorafenib on a large scale. TheApplicant herein has applied and obtained a patent for a processof producing sorafenib, copy of which is annexed herewith asAnnexure-M. The applicant submits that it can manufacture theproduct sorafenib by employing the existing facilities and doesnot require any additional plant/machinery or investment for thesame since the Applicant is already manufacturing other anticancer products.c. Ability of Applicant to market the product:The Applicant submits that they do have the abilities andcapabilities to manufacture the product Sorafenib (should the The Patent Office Journal 12/08/2011 13356
  21. 21. licence be granted) and cater to the needs and necessity of the entire population suffering from rena! cancer and/or hepatic cell carcinoma. d. Proposed Capacity: The Applicant can manufacture the product at the rate of 20,00,000 tablets a day, amounting to about 6,00,00,000 tablets per month. There is a need for supply of 4,80,000 tablets a month, which this Applicant can easily manufacture and supply.e. Proposed Price: The Applicant proposes cost of about Rs 74/- per tablet, working out to Rs 8,880/- per month for treatment to a patient. The Applicant is also ready and willing to manufacture and offer for free the tablets to patients who cannot afford even the proposed price.f. Marketing / Distributor Network: The Applicant has already obtained approval from the Drug Controller General of India for manufacture and marketing of the product Sorafenib in India. A copy of the license granted is The Patent Office Journal 12/08/2011 13357
  22. 22. annexed herewith as Annexure-N.Hence, the Applicant has the potential to manufacture and market the drug in India. The Applicant is already supplying anti cancer products to various hospitals all over India. Its drugs are found with almost all of the chemists all over India. The Applicant has the distribution network in almost every city in India including all the districts in the country. The Applicant is ready and willing to furnish details of its distributors if so called for by the Learned Controller.11. Efforts by Applicant to obtain voluntary licence: The Applicant herein had made independent efforts to obtain licence to manufacture and sell the product Sorafenib in India and by virtue of letter dated 06th Dec 2010, the Applicant had requested the patentee for such licence. The Patentee refused the same vide letter dated 27th Dec 2010. The copies of the said letters dated 06th December 2010 and dated 27th December 2010 are annexed herewith as Annexure-O and Annexure-P respectively.12. The grounds for grant of licence The Applicant submits that in view of the facts and circumstances described above, a prima facie case that reasonable requirements of The Patent Office Journal 12/08/2011 13358
  23. 23. the public not being satisfied and for grant of compulsory licenseis made out because: a. the Applicant herein had made a request for licence which was turned down and refused by the Patentee point blank, without any discussion whatsoever, and on account thereof, establishment of a new trade or industry for supply of Sorafenib to needy patients is severely hampered; b. as explained above, the number of patients and the actual demand in the market for Sorafenib far exceeds the supply thereof by the Patentee and hence the demand for the patented product has not been met to an adequate extent; c. as explained above, the price of the patented product Sorafenib is too high and simply unaffordable by the common man making the product inaccessible and out of reach- hence the demand for the patented product has not been met on reasonable terms; The Patent Office Journal 12/08/2011 13359
  24. 24. d. the Applicant bonafidely believes that the market for exportof the drug to developing and under-developing countries is notbeing supplied or developed;e. on account of refusal of the licence, the establishment of commercial activities in India in respect of the patented product and supply thereof to needy patients is totally prejudiced;f. the patented product is being imported into India by the Patentee and is not manufactured within India- hence the product is not worked in the territory of India to the fullest extent that is reasonably practicable;g. the patented product is available in limited quantities andthat too only in certain select places in certain cities - hence theproduct is not worked in the territory of India to an adequateextent or not worked to the fullest extent that is reasonablypracticable; The Patent Office Journal 12/08/2011 13360
  25. 25. h. the working of the patented product in India is hindered in India due to importation of the patented product from abroad by the patentee and those claiming under him. i. The practice adopted by the Patentee of exorbitantly pricing its patented life-saving product is abuse of its monopolisitic rights and such practice is unfair and anti-competitive;13. The Applicant craves leave to submit certified copies of the Patent document IN 215758 in due course and any other documents as may be called for by this office.14. The terms: After adjudication, should the learned Controller decide to grant compulsory licence in favour of the Applicant herein, the Applicant is prepared to accept the same on the following terms: a, the right to manufacture and sell Sorafenib shall be limited to the territory of India- the Applicant shall not use the licence for sale to other countries. Aplicant shall take all necessary steps to ensure that the product is sold and available only within the territory of India. All products under the Licence shall be marked specifically that they are for sale and use in India only; b, the products under licence shall be manufactured only to cover patients who are afflicted by renal and hepatic carcinoma : preferance shall be given to patients who are economically weak, government welfare schemes and those in backward areas ; The Patent Office Journal 12/08/2011 13361
  26. 26. c. the Applicant agrees to pay a royalty to the Patentee at the rate as fixed by the Ld Controller; d. Applicant agrees to make available the patented product at the most reasonable and affordable price possible. Initially the applicant proposes a price of Rs 74 per tablet which works out to Rs 8880 /- for month for the treatment. e. Agrees to offer the drug free of cost to deserving and needy for their lifetime. The Applicant agrees to be bound by any other terms and conditions as may be imposed by the Ld Controller.15. C.S. (OS) No.1090/2011. It is submitted that the Respondent Bayer Corporation, has filed Civil Suit No. 1090/2011 in the High Court of Delhi against the Applicant alleging infringement of Patent No.215758. The present application has been filed without prejudice to the contentions, rights and liberties of this Applicant in the said suit.16. In view of the above submissions, the Applicant humbly prays that: a) the Ld Controller may be pleased to grant and issue Compulsory licence in favour of the applicant herein in respect of Indian patent no 215758 upon terms and conditions that the Ld Controller may deem fit and proper in the circumstances of the case; The Patent Office Journal 12/08/2011 13362
  27. 27. (iii) such other or further reliefs be granted to meet the ends of justice. VERIFICATIONVerified at Delhi on this 18th day of july,2011 that the contentsof the Reply are based on legal advise received and believed tobe true (save and except fact for which I have relied on mattersof record). No part of it is false and nothing material has beenconcealed therefrom. CONTINUED TO PART-2 The Patent Office Journal 07/07/2011 13363
  28. 28. CONTINUED FROM PART- 1Early Publication:The following patent applications have been published under section 11A (2) of The Patents (Amendment) Act 2005 and rule24A of The Patents (Amendment) Rules, 2006. Any person may file representation by way of opposition to the Controller ofPatents at the appropriate office against the grant of the patent in the prescribed manner under section 25(1) of the Patents(Amendment) Act 2005 read with the rule 55 of The Patents (Amendment) Rules, 2006:(12) PATENT APPLICATION PUBLICATION (21) Application No.386/DEL/2011 A(19) INDIA(22) Date of filing of Application :15/02/2011 (43) Publication Date : 12/08/2011(54) Title of the invention : AN IMPROVED PLANT FOR PREPARING SYNTHETIC GYPSUM.(51) International classification :C04B (71)Name of Applicant :(31) Priority Document No :NA 1)SHREE CEMENT LIMITED(32) Priority Date :NA Address of Applicant :BANGUR NAGAR, BEAWAR(33) Name of priority country :NA 305901, DISTT. - AJMER, RAJASTHAN, INDIA. Rajasthan(86) International Application No :NA India Filing Date :NA (72)Name of Inventor :(87) International Publication No :NA 1)H.M. BANGUR(61) Patent of Addition to Application Number :NA Filing Date :NA(62) Divisional to Application Number :NA Filing Date :NA(57) Abstract :The present invention relates to an improved plant for preparing Synthetic gypsum.No. of Pages : 12 No. of Claims : 8 The Patent Office Journal 12/08/2011 13364
  29. 29. (12) PATENT APPLICATION PUBLICATION (21) Application No.1523/DEL/2010 A(19) INDIA(22) Date of filing of Application :30/06/2010 (43) Publication Date : 12/08/2011(54) Title of the invention : A NOVEL PHARMACEUTICAL COMPOSITION OF CEFPODOXIME AND OFLOXACIN TOTREAT MICROBIAL INFECTIONS(51) International classification :C02F (71)Name of Applicant :(31) Priority Document No :NA 1)AKUMS DRUGS & PHARMACEUTICALS LIMITED(32) Priority Date :NA Address of Applicant : 304, MOHAN PLACE, LSC, BLOCK-(33) Name of priority country :NA C, SARASWATI VIHAR, DELHI-34. Delhi India(86) International Application No :NA (72)Name of Inventor : Filing Date :NA 1)MR. SANJEEV JAIN(87) International Publication No :NA(61) Patent of Addition to Application Number :NA Filing Date :NA(62) Divisional to Application Number :NA Filing Date :NA(57) Abstract :The present invention discloses a pharmaceutical formulation comprising Cefpodoxime and Ofloxacin for the treatment of variety ofbacterial infections. The present invention exhibits a broad spectrum activity, thereby effective against a number of microorganisms.No. of Pages : 11 No. of Claims : 8 The Patent Office Journal 12/08/2011 13365
  30. 30. (12) PATENT APPLICATION PUBLICATION (21) Application No.1120/MUM/2011 A(19) INDIA(22) Date of filing of Application :01/04/2011 (43) Publication Date : 12/08/2011(54) Title of the invention : A SYSTEM AND METHOD FOR FACILITATE DOMAINS AND USERS, APPLICATIONS,SERVICES, OBJECTS, COMMUNICATION CHANNELS OF MULTIPLE DOMAINS TO COMMUNICATE WITH EACHOTHERS.(51) International classification :G06F17/00 (71)Name of Applicant :(31) Priority Document No :NA 1)RATHOD YOGESH CHUNILAL(32) Priority Date :NA Address of Applicant :1502/A MAHAVIR RESIDENCY, L B(33) Name of priority country :NA S MARG, NEAR BALRAJESHWAR MANDIR, MULUND(W),(86) International Application No :NA MUMBAI 400080, MAHARSHTRA, INDIA Filing Date :NA (72)Name of Inventor :(87) International Publication No :N/A 1)RATHOD YOGESH CHUNILAL(61) Patent of Addition to Application Number :NA Filing Date :NA(62) Divisional to Application Number :NA Filing Date :NA(57) Abstract :A system and method for facilitate users of multiple domains to communicate with each other is described. A method includes multidomain communication capable domains including social network enables users to post or share contents to other multi domaincommunication capable domains or external domains, users, applications, services, objects, devices, databases of external domainsand/or present domain. Users may select how content will be published and control the accessibility of uploaded content using aprivacy setting for each content item that the user posts. The privacy setting defines, or identifies, the set of external domainsincluding web sites, applications, services, devices, networks, groups, objects, widgets, web pages and connections or users of presentnetwork who may view the posted content item. The posted content item is placed in a particular web pages, applications, services,objects, communication channel in the social network, such as video sharing, question and answer application, updated status, photoalbums, search engine, deals application, e-commerce service, mobile service where the content item can be viewed by those who arepermitted to view it according to its associated privacy setting. Varying granularities of privacy settings provide flexibility for contentaccessibility on a social network and external domains.No. of Pages : 99 No. of Claims : 72 The Patent Office Journal 12/08/2011 13366
  31. 31. (12) PATENT APPLICATION PUBLICATION (21) Application No.1174/MUM/2011 A(19) INDIA(22) Date of filing of Application :08/04/2011 (43) Publication Date : 12/08/2011(54) Title of the invention : A SYSTEM AND METHOD FOR O-MAIL OR OMNIPRESENT COMMUNICATION, O-MAILADDRESS, O-MAIL SERVICE, O-MAIL CLIENT, O-MAIL SERVER, NETWORK, PLATFORM AND PIN POINTCOMMUNICATION PROTOCOL (PPP)(51) International classification :G06F17/00 (71)Name of Applicant :(31) Priority Document No :NA 1)RATHOD YOGESH CHUNILAL(32) Priority Date :NA Address of Applicant :1502/A MAHAVIR RESIDENCY, L B(33) Name of priority country :NA S MARG, NEAR BALRAJESHWAR MANDIR, MULUND (W),(86) International Application No :NA MUMBAI 400080, MAHARASHTRA, INDIA Filing Date :NA (72)Name of Inventor :(87) International Publication No :N/A 1)RATHOD YOGESH CHUNILAL(61) Patent of Addition to Application Number :NA Filing Date :NA(62) Divisional to Application Number :NA Filing Date :NA(57) Abstract :A system and method for new O-Mail communication protocol, service is described. A method includes system, method, protocol,service, platform, and framework for facilitating anybody can communicate with anybody, anywhere for anything and provide ondemand, integrated, unified, loosely coupled, user friendly, personalize, customize, contextual, interconnected, dynamic, real timecommunication, collaboration and sharing platform based on O-Mail or omnipresent communication, O-Mail address, O-Mail service,O-Mail client, O-Mail Server, network, platform and pin point communication protocol (PPP). A method also includes multi domaincommunication capable domains including social network enables users to post or share contents to other multi domaincommunication capable domains or external domains, users, applications, services, objects, devices, databases of external domainsand/or present domain. Users may select how content will be published and control the accessibility of uploaded content using aprivacy setting for each content item that the user posts. The privacy setting defines, or identifies, the set of external domainsincluding web sites, applications, services, devices, networks, groups, objects, widgets, web pages and connections or users of presentnetwork who may view the posted content item. The posted content item is placed in a particular web page, applications, services,objects, communication channel in the social network where the content item can be viewed by those who are permitted to view itaccording to its associated privacy setting. Varying granularities of privacy settings provide flexibility for content accessibility on asocial network and external domains.No. of Pages : 125 No. of Claims : 46 The Patent Office Journal 12/08/2011 13367
  32. 32. (12) PATENT APPLICATION PUBLICATION (21) Application No.937/MUM/2011 A(19) INDIA(22) Date of filing of Application :28/03/2011 (43) Publication Date : 12/08/2011(54) Title of the invention : PROCESS FOR PREPARATION OF ALKALI METAL IODIDE.(51) International classification :C25B1/24 (71)Name of Applicant :(31) Priority Document No :NA 1)OMKAR SPECIALITY CHEMICALS LTD.(32) Priority Date :NA Address of Applicant :B-34, M.I.D.C., BADLAPUR (E),(33) Name of priority country :NA DIST-THANE 421503, MAHARASHTRA, INDIA.(86) International Application No :NA (72)Name of Inventor : Filing Date :NA 1)MR. OMKAR PRAVIN HERLEKAR(87) International Publication No :N/A(61) Patent of Addition to Application Number :NA Filing Date :NA(62) Divisional to Application Number :NA Filing Date :NA(57) Abstract :The mentioned is a three step process for preparation of alkali metal iodides particularly to sodium iodide and potassium-iodide. Infirst step of reaction, ammonium compounds like ammonium hydroxide, ammonium carbonate and ammonium bicarbonate and iodineare reacted with each other in presence of catalyst like hydrogen peroxide or hydrazine hydrate to form ammonium iodide. In secondstep, reaction between alkaline hydroxide or carbonate or bicarbonate with ammonium iodide takes place to form alkali metal iodide.Evaporation of the obtained solution to form crystals of sodium or potassium iodide in last step.No. of Pages : 15 No. of Claims : 4 The Patent Office Journal 12/08/2011 13368
  33. 33. (12) PATENT APPLICATION PUBLICATION (21) Application No.1134/MUM/2011 A(19) INDIA(22) Date of filing of Application :05/04/2011 (43) Publication Date : 12/08/2011(54) Title of the invention : MULTITHERAPEUTIC NUTRACEUTICAL COMPOSITION OF GANODERMA LUCIDUM(51) International classification :A61K36/00 (71)Name of Applicant :(31) Priority Document No :NA 1)DR. ALKA PRAVIN JAJOO(32) Priority Date :NA Address of Applicant :DEPARTMENT OF(33) Name of priority country :NA BIOTECHNOLOGY SGB AMRAVATI UNIVERSITY(86) International Application No :NA AMRAVATI, 444 602 Maharashtra India Filing Date :NA (72)Name of Inventor :(87) International Publication No :N/A 1)DR. ALKA PRAVIN JAJOO(61) Patent of Addition to Application Number :NA 2)PROF MAHENDRA KUMAR RAI Filing Date :NA 3)MS SHARADA LAXMAN DEORE(62) Divisional to Application Number :NA 4)MR. BHUSHAN A. BAVISKAR Filing Date :NA(57) Abstract :Gonoderma lucidum is a basidiomycete while rot macrofungus which has been used extensively as Elixir of eternal youth in China,Japan, Korea and other Asian countries for more than 2000 years. A great deal of work has been carried out on therapeutic potential ofGonoderma htcidum. The basidiocarp, mycelia and spores of Gonoderma lucidum contain approximately 400 different bioactivecompounds, which mainly include iriterpenoids. polysaccharides, nucleotides, sterols, steroids, fatty acids, proteins/peptides and traceelements which has been reported to have a number of pharmacological effects including immunomodulation. anti-atherosclerotic,anti-inflammatory, analgesic, chemopreventive. antitumor chemo and radio protective, sleep promoting, antibacterial, antiviral(including anti-HIV), hypolipidemic, anti-ftbroiic. hepatoprotective, anti-diabetic, anti-androgenic, anti-angiogenic. anti-herpetic.antioxidative and radical-scavenging, anti-aging, hypoglycemic, estrogenic activity and anti-ulcer properties. Gonoderma lucidum hasnow become recognized as an alternative adjuvant in the treatment of leukemia. carcinoma, hepatitis and diabetes. The inventionrelates 10 the multitherapeutic nutraceulical composition of Gonoderma lucidum as extract and juice and method of use of the same inenhancing the immunity of healthy as well as immune compromised people. The compositions are also used to alleviate age relaleddiseases. The invention also provides Gonoderma lucidum composition in a ready-to-drink form comprising the water solublepolysaccharides and alcohol soluble triterpenoids both therapeutically responsible constituents.No. of Pages : 11 No. of Claims : 10 The Patent Office Journal 12/08/2011 13369
  34. 34. (12) PATENT APPLICATION PUBLICATION (21) Application No.1333/CHE/2010 A(19) INDIA(22) Date of filing of Application :12/05/2010 (43) Publication Date : 12/08/2011(54) Title of the invention : AN HERBAL PAINT COMPOSITION AND MEHTOD OF PREPARATION THEREOF(51) International classification :C09D (71)Name of Applicant :(31) Priority Document No :NA 1)S.AMUTHA(32) Priority Date :NA Address of Applicant :7, N.K.CHETTY(33) Name of priority country :NA STREET,PUDUPET,GUDIYATTAM-632602 Tamil Nadu India(86) International Application No :NA (72)Name of Inventor : Filing Date :NA 1)S.AMUTHA(87) International Publication No : NA(61) Patent of Addition to Application Number :NA Filing Date :NA(62) Divisional to Application Number :NA Filing Date :NA(57) Abstract :The present invention relates to an herbal paint composition. The said herbal paint composition shows improved paint characteristicssuch as shine, grip and the like, simultaneously proving to be a potent insect and pest resistant, wood-corrosion resistant, eco-friendlywith no harmful side effects. The present invention also relates to a method of preparation of the said herbal paint compositionNo. of Pages : 28 No. of Claims : 10 The Patent Office Journal 12/08/2011 13370
  35. 35. (12) PATENT APPLICATION PUBLICATION (21) Application No.1334/CHE/2010 A(19) INDIA(22) Date of filing of Application :12/05/2010 (43) Publication Date : 12/08/2011(54) Title of the invention : HERBAL PAIN REMOVER OIL COMPOSITION AND METHOD OF PREPARATION(51) International classification :A61K31/00 (71)Name of Applicant :(31) Priority Document No :NA 1)S. AMUTHA(32) Priority Date :NA Address of Applicant :7, N.K. CHETTY STREET,(33) Name of priority country :NA PUDUPET, GUDIYATTAM - 632602 Tamil Nadu India(86) International Application No :NA (72)Name of Inventor : Filing Date :NA 1)S. AMUTHA(87) International Publication No : NA(61) Patent of Addition to Application Number :NA Filing Date :NA(62) Divisional to Application Number :NA Filing Date :NA(57) Abstract :The present invention provides a herbal oil based composition prepared from a blend of herbs and essential oils that comprisesCamphor Oil, Menthol Oil, Homa Slat Oil (Thymol Oil), Bamboo Salt and Thipili (Piper longum) The herbal oil based composition inaccordance with the present invention is effective in curing common aches and pains like headaches, back pain and others such asasthma, inflammation and the like. The herbal composition provides relief and removes pain by topically applied it on the arearequired to be treated. The present invention also provides a method for the preparation of the said herbal pain remover oilcomposition.No. of Pages : 23 No. of Claims : 7 The Patent Office Journal 12/08/2011 13371
  36. 36. (12) PATENT APPLICATION PUBLICATION (21) Application No.2432/CHE/2011 A(19) INDIA(22) Date of filing of Application :16/07/2011 (43) Publication Date : 12/08/2011(54) Title of the invention : LIGHTING FOR SPORTS STADIUMS AND OUTDOOR ARENAS(51) International classification :F21S2/00 (71)Name of Applicant :(31) Priority Document No :NA 1)K. Vishweswar Reddy(32) Priority Date :NA Address of Applicant :35 Sai Enclave Avenue 1 Road No. 12(33) Name of priority country :NA Banjara Hills Hyderabad Andhra Pradesh Andhra Pradesh India(86) International Application No :NA (72)Name of Inventor : Filing Date :NA 1)K. Vishweswar Reddy(87) International Publication No : NA(61) Patent of Addition to Application Number :NA Filing Date :NA(62) Divisional to Application Number :NA Filing Date :NA(57) Abstract :A lighting system for illuminating large spaces which uses tethered lighter than air balloons with LEDs mounted on its lower surfacefacing the ground. There are several such lighter than air balloons with LEDs tethered around the ground and floating high above.Each of the balloons is tethered by two or more tethering ropes to avoid movement due to wind. Such a lighting system is easy todeploy, does not require permanent structures, is transportable and relatively lower in cost.No. of Pages : 10 No. of Claims : 5 The Patent Office Journal 12/08/2011 13372
  37. 37. (12) PATENT APPLICATION PUBLICATION (21) Application No.2570/CHE/2011 A(19) INDIA(22) Date of filing of Application :27/07/2011 (43) Publication Date : 12/08/2011(54) Title of the invention : SELF-CENTERING WHEEL ARRESTING AND LIFTING MECHANISM FOR MULTILEVELVEHICLE PARKING SYSTEM :B60S, (71)Name of Applicant :(51) International classification E04H6/06 1)Mr. K. T. Jose(31) Priority Document No :NA Address of Applicant :Kulangara House South attara(32) Priority Date :NA Kokkunnu(via) Mookkannur P.O 683577 Ankamaly Kerala(33) Name of priority country :NA Kerala India(86) International Application No :NA (72)Name of Inventor : Filing Date :NA 1)Mr. K. T. Jose(87) International Publication No : NA(61) Patent of Addition to Application Number :NA Filing Date :NA(62) Divisional to Application Number :NA Filing Date :NA(57) Abstract :In view of the foregoing, an embodiment herein provides a self-centering unit on a collection-delivery rack of a parking system forsecure arresting of wheels of a vehicle. Specifically, the self-centering unit includes a plurality of wheel-arresting rods that can foldand unfold with the help of hydraulic jackeys. The movement of a pair of wheel-arresting rods is relative to one another and as theserods unfold towards the wheel, the self-centering unit not only centers the wheel automatically but also securely arrests the wheel andlifts the vehicle off the ground.No. of Pages : 21 No. of Claims : 11 The Patent Office Journal 12/08/2011 13373
  38. 38. (12) PATENT APPLICATION PUBLICATION (21) Application No.1908/CHE/2011 A(19) INDIA(22) Date of filing of Application :06/06/2011 (43) Publication Date : 12/08/2011(54) Title of the invention : PREPARATION OF 2-(4-BROMOPHENYL)-2-METHYLPROPANOIC ACID(51) International classification :C07C17/00 (71)Name of Applicant :(31) Priority Document No :NA 1)DIVIS LABORATORIES LIMITED(32) Priority Date :NA Address of Applicant :7-1-77/E/1/303, DIVI TOWERS,(33) Name of priority country :NA DHARAM KARAN ROAD, AMEERPET, HYDERABAD - 500(86) International Application No :NA 016 Andhra Pradesh India Filing Date :NA (72)Name of Inventor :(87) International Publication No : NA 1)MURALI KRISHNA PRASAD DIVI(61) Patent of Addition to Application Number :NA 2)GUNDU RAO PADAKANDLA Filing Date :NA 3)NAGWESWARA RAO BOLNENI(62) Divisional to Application Number :NA 4)KRISHNAJI RAO MUTYALA Filing Date :NA(57) Abstract :Preparation of 2-(4-Bromophenyl)-2-Methylpropanoic Acid Selective bromination of 2-methyl-2-phenylpropanoic acid in aqueousmedium is described to obtain pure 2-(4-bromophenyl)-2-methylpropanoic acid, which is a useful key intermediate in the process ofmanufacturing pure fexofenadine.No. of Pages : 14 No. of Claims : 3 The Patent Office Journal 12/08/2011 13374
  39. 39. (12) PATENT APPLICATION PUBLICATION (21) Application No.2657/CHE/2011 A(19) INDIA(22) Date of filing of Application :03/08/2011 (43) Publication Date : 12/08/2011(54) Title of the invention : NEW BARBITURATES OF NITRO AROMATIC COMPOUNDS AS ANTI CONVULSANTS,HYPNOTIC AGENTS, DYES AND FLUORESCENT MOLECULES (71)Name of Applicant :(51) International classification :A61K31/00 1)DR. D. KALAI VANI(31) Priority Document No :NA Address of Applicant :ASSOCIATE PROFESSOR,(32) Priority Date :NA DEPARTMENT OF CHEMISTRY, SEETHALAKSHMI(33) Name of priority country :NA RAMASWAMI COLLEGE, TIRUCHIRAPPALLI - 620 002(86) International Application No :NA Tamil Nadu India Filing Date :NA (72)Name of Inventor :(87) International Publication No : NA 1)DR. D. KALAI VANI(61) Patent of Addition to Application Number :NA 2)MS. R. BABY KALA Filing Date :NA 3)MS. G. MANGAIYARKARSI(62) Divisional to Application Number :NA 4)MS. V. MANICKKAM Filing Date :NA 5)MS. G. SRIDEVI 6)MS. R. RAJAMANI(57) Abstract :New solid barbiturates of high purity have been synthesized from the ethanolic solution of aromatic nitro compounds (l-chloro-2,4-dinitrobenzene, l,3-dichloro-4,6- dinitrobenzene or l-chloro-2,4,6-trinitrobenzene) and barbituric acid/thiobarbituric acid / N,N-dimethylbarbituric acid in the presence of bases such as trimethylamine, triethylamine, tri-n-butylamine, triethanolamine, N,N-diethylaminoethanol, substituted N,N-dimethylaniline, substituted N,N-diethylaniline, substituted pyridine, substituted quinoline andl,4-diazabicyclo[2.2.2]octane (DABCO). Spectral charaterisation (uv- vis, ir, pmr, 13C nmr and mass) has been performed on thesynthesized barbiturates. Elemental analysis and other qualitative tests have also been carried out. Single crystal X-ray diffractionstudies have been undertaken with some of the crystalline barbiturates to confirm the structures. Maximal Electro Shock (MES)method has been employed to examine their anticonvulsant activity. Reduction in extensor phase of convulsion has been noticed forthe synthesized barbiturates. LD50 values of the barbiturates have been assessed in animal model. LD50 values fall under class 4(>1000 mg/kg) and the animals did not show any sign of acute toxicity and behavioral changes. Therapeutic dose of the newbarbiturates induce hypnosis in albino mice of either sex weighing 25-30 grams. Some of the intensely coloured barbiturates havefixing ability on cotton, wool and polyester in the presence of mordants. Solid state emission spectra of some of the isolatedbarbiturates reveal that they are fluorescent molecules.No. of Pages : 29 No. of Claims : 9 The Patent Office Journal 12/08/2011 13375
  40. 40. (12) PATENT APPLICATION PUBLICATION (21) Application No.2673/CHE/2011 A(19) INDIA(22) Date of filing of Application :04/08/2011 (43) Publication Date : 12/08/2011(54) Title of the invention : A MOBILE ADVERTISING DISPLAY SYSTEM AND A METHOD FOR DYNAMIC TARGETTINGOF LOCATION BASED ADVERTISEMENTS(51) International classification :G06Q (71)Name of Applicant :(31) Priority Document No :NA 1)MR. KOPURI AMARNATH(32) Priority Date :NA Address of Applicant :6-1-1059, FLAT NO.307, TAJ(33) Name of priority country :NA ENCLAVE, BESIDE SENSATION THEATRE,(86) International Application No :NA KHAIRATHABAD, HYDERABAD - 500 004 Andhra Pradesh Filing Date :NA India(87) International Publication No : NA (72)Name of Inventor :(61) Patent of Addition to Application Number :NA 1)MR. KOPURI AMARNATH Filing Date :NA(62) Divisional to Application Number :NA Filing Date :NA(57) Abstract :A mobile advertising display system and method for dynamic targeting of location based advertisements are disclosed. The systemincludes a pair of supporting members and a detachable advertisement display panel comprising a front advertisement display and arear advertisement display secured to the pair of supporting members. The method includes determining a current location of anautomobile by utilizing a location determination module, utilizing a dynamic data management module positioned at the centralmonitoring station for receiving the current location of the automobile, whereby the dynamic data management modulecommunicatively coupled with a memory module for transmitting the location based advertisement in response to the received currentlocation of the automobile and enabling a process of dynamic transmission of location based advertisements by the dynamic datamanagement module to the data communication module for displaying on the display panel elevated above an upper surface of theautomobile.No. of Pages : 24 No. of Claims : 12 The Patent Office Journal 12/08/2011 13376
  41. 41. (12) PATENT APPLICATION PUBLICATION (21) Application No.2489/CHE/2011 A(19) INDIA(22) Date of filing of Application :20/07/2011 (43) Publication Date : 12/08/2011(54) Title of the invention : SYSTEM FOR PROVIDING SUPPLY CHAIN OPERATIONS AS A SERVICE(51) International classification :G06Q (71)Name of Applicant :(31) Priority Document No :NA 1)HCL Technologies Ltd.(32) Priority Date :NA Address of Applicant :50-53 Greams Road Chennai - 600006(33) Name of priority country :NA Tamil Nadu India.(86) International Application No :NA (72)Name of Inventor : Filing Date :NA 1)Nipun Kohli(87) International Publication No : NA(61) Patent of Addition to Application Number :NA Filing Date :NA(62) Divisional to Application Number :NA Filing Date :NA(57) Abstract :A system for providing supply chain operations as a service in a cloud computing environment across a plurality of tenants comprisingof:-an order management module configured to manage incoming orders and track their status;-a billing module coupled to the ordermanagement module configured to carry out accounting and financial transactions;-a customer ERP module coupled to the servicebilling module and order management module configured to manage and implement customer related activities;-one or more servicemodules each coupled to the order management module configured to carry out supply chain management activities; and-ne or moreinterfaces configured to connect with one or more external entities;No. of Pages : 18 No. of Claims : 15 The Patent Office Journal 12/08/2011 13377
  42. 42. (12) PATENT APPLICATION PUBLICATION (21) Application No.748/KOL/2011 A(19) INDIA(22) Date of filing of Application :01/06/2011 (43) Publication Date : 12/08/2011(54) Title of the invention : A SYNERGISTIC INSECTICIDAL COMPOSITION OF CARTAP HYDROCHLORIDE ANDBUPROFEZIN (71)Name of Applicant :(51) International classification :A01N37/00 1)KRISHI RASAYAN EXPORTS PVT. LTD.(31) Priority Document No :NA Address of Applicant :FMC FORTUNA, 4TH FLOOR,(32) Priority Date :NA BLOCK A-11, 234/3A, A.J.C. BOSE ROAD, KOLKATA-(33) Name of priority country :NA 700020, WEST BENGAL, INDIA CORPORATE OFFICE 1115,(86) International Application No :NA MODI TOWER, 98, NEHRU PLACE, NEW DELHI-110019, Filing Date :NA India(87) International Publication No : NA (72)Name of Inventor :(61) Patent of Addition to Application Number :NA 1)ATUL CHURIWAL Filing Date :NA 2)DR. DIPANKAR PATRA(62) Divisional to Application Number :NA 3)ABHISHEK MUKHERJEE Filing Date :NA 4)DR. BIJAN MAITI(57) Abstract :The present invention relates to a Novel insecticidal composition which is effective in controlling insect pests. More particularly, thepresent invention relates to insecticidal composition which is prepared by using the two potent insecticides, Cartap hydrochloride andBuprofezin with some adjuvant and stabilizing agent. Further this composition which displays a synergistically enhanced activityagainst insects is useful for controlling plant pests. Moreover this invention relates to the process for the preparation of the aboveinsecticidal composition. It is particularly effective in combating or preventing insect causing crop loss. These combinations exhibitsynergistic insecticidal activity.No. of Pages : 19 No. of Claims : 13 The Patent Office Journal 12/08/2011 13378
  43. 43. (12) PATENT APPLICATION PUBLICATION (21) Application No.916/KOL/2011 A(19) INDIA(22) Date of filing of Application :08/07/2011 (43) Publication Date : 12/08/2011(54) Title of the invention : AN UNIQUE SYSTEM OF ELECTRIC POWER GENERATION BY THE HELP OF OCEAN TIDALENERGY & GRAVITATIONAL ENERGY(51) International classification :H02N6/00 (71)Name of Applicant :(31) Priority Document No :NA 1)RAJ KUMAR BAGH(32) Priority Date :NA Address of Applicant :6/4, TARACHAND POLLEY LANE,(33) Name of priority country :NA HOWRAH, WEST BENGAL, PIN-711101 India(86) International Application No :NA (72)Name of Inventor : Filing Date :NA 1)RAJ KUMAR BAGH(87) International Publication No : NA(61) Patent of Addition to Application Number :NA Filing Date :NA(62) Divisional to Application Number :NA Filing Date :NA(57) Abstract :This process will minimize the problem of Electric Power Generation. Combine utilization of Ocean tide and Gravitational force cangenerates a huge power by specially design tank and process. From the Sketch-1 we can elastrat the process in brief:- 1. When theocean is in high tide position, water from ocean will enter the Primary Tank through Tunnels & lock gate. 2. From Primary Tank thewater will also enter to the Secondary Tank. 3. The secondary tank consist of nos of cylindrical tank with weighted Plungers are fittedat the top. 4. The outlet pipe from the base of the secondary tank is connected to a common Header through pipe fittings. 5. FromHeader, Pipes are connected to Turbine fitted with Alternator. 6. Water from Turbines Outlets discharge to common Channel. 7.Channel is connected with a Rough Tank through lock gate. 8. From Rough Tank water will discharge to ocean though a lock gatewhen low tide, otherwise if required discharge to Primary tank through pipe & fittings. 9. The weighted Plunger fitted on theSecondary Cylindrical Tank will act like a Hydraulic Machine and generates a huge Pressure Head at the Tank bottom as well as Inletpipe of Turbine. 10. High tide Ocean is a huge source of water and the Gravitational Energy is the cause of increasing Pressure Headof water can run the Turbine fitted with Alternator and generates Huge Electrical Power.No. of Pages : 17 No. of Claims : 10 The Patent Office Journal 12/08/2011 13379
  44. 44. Publication After 18 Months:The following Patent Applications have been published under Section 11A (3) of The Patents (Amendment) Act, 2005. AnyPerson may file representation by way of opposition to the Controller of Patents at the appropriate office against the grant ofthe patent in the prescribed manner under section 25(1) of the Patents (Amendment) Act, 2005 read with the rule 55 of ThePatents (Amendment) Rules, 2006:(12) PATENT APPLICATION PUBLICATION (21) Application No.2443/DEL/2009 A(19) INDIA(22) Date of filing of Application :27/11/2009 (43) Publication Date : 12/08/2011(54) Title of the invention : AN EMBEDDED SYSTEM FOR ANALYSIS OF MICROSTRIP-LIKE INTERCONNECTS(51) International classification :G01R29/08; (71)Name of Applicant :(31) Priority Document No :NA 1)JAYPEE UNIVERSITY OF INFORMATION(32) Priority Date :NA TECHNOLOGY, WAKNAGHAT(33) Name of priority country :NA Address of Applicant :P.O. DUMEHAR BANI,(86) International Application No :NA KANDAGHAT, DISTT. SOLAN-173215 Himachal Pradesh Filing Date :NA India(87) International Publication No : NA (72)Name of Inventor :(61) Patent of Addition to Application Number :NA 1)DR. ROHIT SHARMA Filing Date :NA(62) Divisional to Application Number :NA Filing Date :NA(57) Abstract :Disclosed are computing device and methods for computing electrical characteristics of interconnect lines. The computing deviceincludes at least one processor and at least one memory comprising computer program code. The at least one memory and thecomputer program code configured to, with the at least one processor, cause the computing device to receive interconnect inputassociated with an interconnect line and calculate a Greens function corresponding to the geometrical dimensions. The interconnectinput includes geometrical dimensions of the interconnect line and at least one material constant. The Greens function is calculatedusing transverse transmission line technique. Furthermore, the at least one memory and the computer program code configured to,with the at least one processor, cause the computing device at least to compute one or more electrical characteristics of theinterconnect line based on at least one of the geometrical dimension, the Greens function and a variational analysis.No. of Pages : 28 No. of Claims : 14 The Patent Office Journal 12/08/2011 13380

×